Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body treat­ments

It’s the end of the road for Voy­ager Ther­a­peu­tics’ col­lab­o­ra­tion with Ab­b­Vie on tau and al­pha-synu­cle­in vec­tor­ized an­ti­body de­vel­op­ment.

In two deals span­ning the last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.